Objective
Heart failure (HF) is a major health problem worldwide because of the high number of patients and the related costs. Current treatments are not consistently efficacious and fail to address the major underlying cause of HF: the massive loss of cardiomyocytes in damaged regions. REGeRNA has been designed to address this issue by leveraging advances in synthetic mRNAs and their lipid nanoparticle (LNP)-based carriers to generate a construct able to reactivate mechanisms mediating cardiomyocyte proliferation in development but which are shut-down shortly after birth. REGeRNA is organised in 6 work packages that follow a roadmap towards endogenous heart repair. The program starts tailoring various human assays and in vitro models such that they can reliably document cardiomyocyte proliferation. These will then be used for screening pathways thought to be involved in cardiomyocyte division, among which Hippo is our primary candidate. mRNA(s) encoding the relevant proteins will be subsequently synthesised and engineered such that their expression is restricted to cardiomyocytes and no stromal cell expansion occurs. An LNP formulation will then be developed for incorporation of the synthesized mRNA(s) and optimized for cardiomyocyte-specific delivery. Subsequently, we will test the mRNA+LNP construct in our human model systems and in mouse models of myocardial ischaemia/reperfusion including transgenic strains that allow unequivocal assessment of cardiomyocyte division in vivo. We will then construct a GMP production line for the mRNA-LNP encapsulation technology to generate pilot batches for pig studies entailing catheter-based endomyocardial injection of the construct in a similar myocardial ischaemia/reperfusion model. The final work package will be responsible for the management and coordination of the project, dissemination, intellectual property management and exploitation of REGeRNA results. This program is framed from the onset to lead to a phase 1 trial at completion
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins
- engineering and technology nanotechnology nano-materials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.2.1.5 - Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-RIA - HORIZON Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-HLTH-2021-TOOL-06
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
75654 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.